Performance Enhancing Drugs Market 2018 – Top Players are Taj Pharmaceuticals Limited. (India), Balkan Pharmaceuticals. (Europe), Bayer AG (Europe), etc. and forecast up to 2023

Performance Enhancing Drugs Market is segmented on the basis of types, products, and end users. On the basis of types, the market is segmented into ergogenic aids, nootropic, and others. The ergogenic aids segment by types is sub-segmented into anabolic steroids, dehydroepiandrosterone (DHEA), human growth hormone, and others. The nootropic segment by types is further segmented into racetams, ampakines, choline & acetylcholine intermediates, others.

On the basis of the products, the market is categorised into pills, injections, patches, and others. On the basis of end users, the market is segmented into athletes, body builders, students, militaries, and others.

Access Sample Copy @ https://www.marketresearchfuture.com/sample_request/4695 .

Key players for global performance enhancing drugs market:

The key players in the global performance enhancing drugs market are Taj Pharmaceuticals Limited. (India), Balkan Pharmaceuticals. (Europe), Bayer AG (Europe), AstraZeneca (Europe), Novo Nordisk A/S (Europe), BrainAlert, LLC (U.S.), Douglas Laboratories. (U.S.), Onnit Labs, LLC. (U.S.), Eli Lilly and Company. (U.S.), and others.

Market Scenario:

Global market for performance enhancing drugs is expected to grow at an approximate CAGR of 4.8%. Performance enhancing drugs are chemical agents designed to provide an advantage in athletic performance. Muscle enlargement, increased blood’s oxygen carrying capacity are some of the effects induced by the consumption of the performance enhancing drugs. In 2015, according to Health Research Funding ~1,084,000 Americans were reported to use anabolic performance enhancing drugs. Along with such trends in the usage of the performance enhancing drugs, increasing acceptance is facilitating the market growth. Approximately 57% of the steroid users said that they would continue to use steroids even if it shortens there life. Moreover, increasing use of the anabolic steroids for the treatment of medical conditions such as anaemia, certain kinds of breast cancer besides others is expected to fuel the market growth during the forecasted period. However, the use of such drugs leads to various side effects. Some of the side effects observed in males are acne, diminished sperm production; in females, masculinization, heart attack, etc. Moreover, in 2014 according to the Health Research Funding, the percentage of positive tests for anabolic drugs doping in world was about 50.6%. Such cases of doping made the governments to formulate strict guidelines for the usage and sales of performance enhancing drugs. This is expected to restrict the market growth during the forecasted period.

Segmentation:

The global performance enhancing drugs market is segmented on the basis of types, products, and end users. On the basis of types, the market is segmented into ergogenic aids, nootropic, and others. The ergogenic aids segment by types is sub-segmented into anabolic steroids, dehydroepiandrosterone (DHEA), human growth hormone, and others. The nootropic segment by types is further segmented into racetams, ampakines, choline & acetylcholine intermediates, others. On the basis of the products, the market is categorised into pills, injections, patches, and others. On the basis of end users, the market is segmented into athletes, body builders, students, militaries, and others.

Regional Analysis:

The Americas dominates the global performance enhancing drugs market owing to the presence of well-developed economies with high per capita income within the region like the U.S. and Canada. In 2017, according to the American Cancer Society in the U.S., about 252,710 new cases of invasive breast cancer diagnosed in women. Moreover, it is predicted that by the end of 2017, 40,610 women would die from breast cancer. This will boost the market growth during the forecasted period as anabolic steroids can be for the treatment of certain types of breast cancer.

Get Discount on Performance Enhancing Drugs Market Report @ https://www.marketresearchfuture.com/check-discount/4695 .

Europe is the second largest performance enhancing drug market, which is followed by Asia Pacific. Availability of funds for research and increasing acceptance of the performance enhancing drugs within the region likely to boost the market.

Asia Pacific is the fastest growing region for the market due to the increasing awareness of the performance enhancing drugs, continuously developing economies, and presence of huge opportunity in the market.

On the other hand, the Middle East & Africa owns the least share of the global performance enhancing drugs market due to presence of poor economy, especially, in Africa region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.

Table of Content:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

Continued…

Browse Full Report @ https://www.marketresearchfuture.com/reports/performance-enhancing-drugs-market-4695 .

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.